Technical Analysis for ATNX - Athenex, Inc.
|Grade||Last Price||% Change||Price Change|
ATNX closed up 0.7 percent on Friday, January 19, 2018, on 85 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical ATNX trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 19||MACD Bullish Centerline Cross||Bullish||0.00%|
|Jan 19||Stochastic Reached Overbought||Strength||0.00%|
|Jan 19||Wide Bands||Range Expansion||0.00%|
|Jan 19||Above Upper BB||Strength||0.00%|
|Jan 19||Overbought Stochastic||Strength||0.00%|
|Jan 19||Up 3 Days in a Row||Strength||0.00%|
|Jan 19||Up 4 Days in a Row||Strength||0.00%|
|Jan 19||Up 5 Days in a Row||Strength||0.00%|
|Jan 19||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 18||50 DMA Support||Bullish||0.70%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ATNX news...
|52 Week High||20.79|
|52 Week Low||11.21|
|200-Day Moving Average||0.0|
|50-Day Moving Average||16.6462|
|20-Day Moving Average||16.1795|
|10-Day Moving Average||16.111|
|Average True Range||0.6544|
|Chandelier Exit (Long, 3 ATRs )||15.5368|
|Chandelier Exit (Short, 3 ATRs )||17.0632|
|Upper Bollinger Band||17.2869|
|Lower Bollinger Band||15.0721|
|Percent B (%b)||1.02|
|MACD Signal Line||-0.1763|
|Market Cap||988.91 Million|
|Num Shares||57.1 Million|
|Price-to-Earnings (P/E) Ratio||-4.99|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||18.02|
|Resistance 3 (R3)||18.00||17.75||17.91|
|Resistance 2 (R2)||17.75||17.57||17.76||17.87|
|Resistance 1 (R1)||17.54||17.47||17.42||17.56||17.83|
|Support 1 (S1)||17.08||17.11||16.96||17.10||16.83|
|Support 2 (S2)||16.83||17.01||16.84||16.79|
|Support 3 (S3)||16.62||16.83||16.76|
|Support 4 (S4)||16.64|